Home › Employers › Beyondspring Pharmaceuticals, Inc.
Beyondspring Pharmaceuticals, Inc.: H-1B salaries and sponsorship
Beyondspring Pharmaceuticals, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $95,000.
Does Beyondspring Pharmaceuticals, Inc. sponsor H-1B visas?
Beyondspring Pharmaceuticals, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Jul 1, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Green card (PERM) applications at Beyondspring Pharmaceuticals, Inc.: 3 →
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Food and Drug Research Scientist | 1 | — |
| Accountant | 1 | $107,000 |
| HR Specialist | 1 | $83,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | — |
| FY2025 | 2 | $95,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| HR Specialist | $83,000 Level II | Florham Park, NJ | Jul 1, 2025 | Sep 6, 2025 | Certified |
| Accountant | $107,000 Level I | Florham Park, NJ | Apr 21, 2025 | Oct 5, 2025 | Certified |
| Food and Drug Research Scientist | $64,522 part-time · Level I | New York, NY | Apr 14, 2023 | May 1, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).